Reports of cardiac adverse events from oncology clinical trials often are at variance with
reports derived from clinical observations or data-base reviews. These differences may lead …

Cardiovascular disease (CVD) is the leading competing cause of mortality in patients with
cancer. 1 Cancer and CVD have shared risk factors that independently increase the …

cardiotoxins, including anthracyclines, erb-b2–targeting agents, and chest radiation are
widely used in breast cancer and other malignancies, and observational data suggest that …

Background Cardiovascular disease (CVD) has become an increasingly common limitation
to effective anticancer therapy. Yet, whether CVD events were consistently reported in …

Introduction: Patients with cancer are subject to the cardiotoxic effects of cancer therapy and
as more patients survive cancer due to improved treatment they are exposed to various …

The development of cardiovascular toxicity attributable to anticancer drugs is a pivotal event
that is associated with cardiovascular morbidity as well as with worse cancer‐specific and …

Introduction: Patients with cancer are subject to the cardiotoxic effects of cancer therapy.
Improved cancer treatments lead to more cancer-survivors, who though are exposed to …

Acknowledging uncertainties and balancing the opportunity for benefit with the offsetting
potential to harm are integral concepts for clinical decision-making. Caregivers consciously …

Methods| Leveraging the Drugs@ FDA database, and publicly available FDA drug reviews,
we manually identified all anticancer drugs and biologics given new drug applications by the …

The considerable progress made in the field of cancer treatment has led to a dramatic
improvement in the prognosis of patients with cancer. However, toxicities resulting from …